Physician profile
Susan Bazinet
NPI 1134150345
$2,627.59
in general payments reported to CMS, 2019-2025
37 companies · $1,059 in 2025
The $1,059 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.92 · 2022: $47.21 · 2023: $785 · 2024: $725 · 2025: $1,059.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,113 · Education: $456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,112.50 |
| Education | $455.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $455.96 | 2023 | |
| Merck Sharp & Dohme LLC | $245.89 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Novartis Pharmaceuticals Corporation | $223.52 | 2024-2025 | |
| Daiichi Sankyo INC. | $123.78 | 2024-2025 | Enhertu, Datroway |
| Amgen INC. | $119.38 | 2025 | Imdelltra (Amg757) |
| G1 Therapeutics, INC. | $118.50 | 2023 | Cosela |
| Array Biopharma INC | $102.14 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Pfizer INC. | $101.85 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $98.52 | 2023-2025 | Opdivo |
| Janssen Biotech, INC. | $82.04 | 2023 | Rybrevant |
| Celgene Corporation | $73.21 | 2024-2025 | Reblozyl, Opdivo |
| Abbvie INC. | $70.15 | 2025 | |
| Gilead Sciences, INC. | $67.73 | 2021-2025 | Trodelvy |
| Puma Biotechnology, INC. | $60.39 | 2023-2024 | |
| Geron Corporation | $57.67 | 2025 | Rytelo |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Bazinet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.